Prostaglandin E2 receptor · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Prostaglandin E2 receptor shows late clinical disease relevance led by benign muscle neoplasm. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P34995. Start with benign muscle neoplasm, then reuse UniProt P34995 as the stable protein anchor across project notes and exports.
Start with benign muscle neoplasm, then reuse UniProt P34995 as the stable protein anchor across project notes and exports.
Prostaglandin E2 receptor shows late clinical disease relevance led by benign muscle neoplasm. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with benign muscle neoplasm because it currently carries late clinical support. Linked drugs include DINOPROSTONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProstaglandin E2 receptor EP1 subtype
Review this target as Prostaglandin E2 receptor, mapped to UniProt P34995. ChEMBL maps the protein component as Prostaglandin E2 receptor EP1 subtype. Sequence length is 402 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin E2 receptor as ChEMBL target CHEMBL2363068, mapped to UniProt P34995. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Prostaglandin E2 receptor is the right protein anchor across sources, using UniProt P34995 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why benign muscle neoplasm is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Prostaglandin E2 receptor |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P34995 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Prostaglandin E2 receptor EP1 subtype |
| UniProt Accession | P34995 |
| Component Type | Protein |
| Sequence Length | 402 aa |
Prostaglandin E2 receptor EP1 subtype
Review this target as Prostaglandin E2 receptor, mapped to UniProt P34995. ChEMBL maps the protein component as Prostaglandin E2 receptor EP1 subtype. Sequence length is 402 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Prostaglandin E2 receptor shows late clinical disease relevance led by benign muscle neoplasm. 4 more disease programs remain visible in the same review block.
Start review with benign muscle neoplasm because it currently carries late clinical support. Linked drugs include DINOPROSTONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.